Recently, sirolimus, a mammalian target of rapamycin inhibitor, has been increasingly used for complicated vascular malformations [21], and the targeted PIK3CA inhibitor alpelisib (BYL719) was recently administered with significant clinical benefit in SVMs in the PIK3CA-related overgrowth spectrum [22]. The gene discussed is PIK3CA; the disease is vascular malformation.